Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 234937, 6 pages
http://dx.doi.org/10.1155/2012/234937
Research Article

Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects

1Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
2Department of Biochemistry, Faculty of Medicine, Sana’a, Yemen
3Department of Medicine, University Malaya Medical Centre, University of Malaya, 50603 Kuala Lumpur, Malaysia
4Faculty of Dentistry, Ibb University, Ibb, Yemen

Received 16 October 2011; Revised 5 February 2012; Accepted 15 February 2012

Academic Editor: Leonid Medved

Copyright © 2012 Zaid Al-Hamodi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation Diabetes Atlas, http://www.eatlas.idf.org/prevalence/.
  2. S. M. Sadikot and C. E. Mogensen, “Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study,” Diabetes Research and Clinical Practice, vol. 82, no. 3, pp. 391–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Zimmet, K. G. M. M. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. C. Alessi and I. Juhan-Vague, “PAI-1 and the metabolic syndrome: links, causes, and consequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200–2207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. Al-Hamodi, I. S. Ismail, R. Saif-Ali, K. A. Ahmed, and S. Muniandy, “Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects,” Cardiovascular Diabetology, vol. 10, article 6, 2011. View at Publisher · View at Google Scholar
  7. Anna., Mechanisms and Effects of Low Plasminogen Activator Inhibitor Type 1 Activity, Karolinska Institutet, 2008.
  8. C. Lopes, C. Dina, E. Durand, and P. Froguel, “PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population,” Diabetologia, vol. 46, no. 9, pp. 1284–1290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Juhan-Vague, P. E. Morange, H. Aubert et al., “Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 867–873, 2002. View at Publisher · View at Google Scholar
  10. M. W. Mansfield, M. H. Stickland, and P. J. Grant, “Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus,” Thrombosis and Haemostasis, vol. 74, no. 3, pp. 842–847, 1995. View at Google Scholar · View at Scopus
  11. M. Freeman and M. Mansfield, “To: J. Hoffstedt et al. (2002) The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity,” Diabetologia, vol. 45, no. 11, pp. 1602–1604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Hoffstedt, I. L. Andersson, L. Persson, B. Isaksson, and P. Arner, “The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity,” Diabetologia, vol. 45, no. 4, pp. 584–587, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Viitanen, J. Pihlajamäki, P. Halonen et al., “Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease,” Atherosclerosis, vol. 157, no. 1, pp. 57–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Tishkoff, G. Ruano, J. R. Kidd, and K. K. Kidd, “Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans,” Human Genetics, vol. 97, no. 6, pp. 759–764, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. G. E. Novick, C. C. Novick, J. Yunis et al., “Polymorphic Alu insertions and the Asian origin of native American populations,” Human Biology, vol. 70, no. 1, pp. 23–39, 1998. View at Google Scholar · View at Scopus
  16. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome—a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. WHO, “Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation,” in Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation, 2006. View at Google Scholar
  18. B. Y. Kang and K. O. Lee, “Genetic polymorphisms of t-PA and PAI-1 genes in the Korean population,” Korean Journal of Biological Sciences, vol. 7, pp. 249–253, 2003. View at Google Scholar
  19. T. Y. H. Wong, P. Poon, C. C. Szeto, J. C. N. Chan, and P. K. T. Li, “Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients,” Kidney International, vol. 57, no. 2, pp. 632–638, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Ezzidi, N. Mtiraoui, M. Chaieb, M. Kacem, T. Mahjoub, and W. Y. Almawi, “Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients,” Diabetes and Metabolism, vol. 35, no. 3, pp. 214–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. K. Nagi, L. J. McCormack, V. Mohamed-Ali, J. S. Yudkin, W. C. Knowler, and P. J. Grant, “Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes,” Diabetes Care, vol. 20, no. 8, pp. 1304–1309, 1997. View at Google Scholar · View at Scopus
  22. M. Broch, C. Gutierrez, C. Aguilar, I. Simon, C. Richart, and J. Vendrell, “Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy,” Diabetes Care, vol. 21, no. 3, article 463, 1998. View at Google Scholar · View at Scopus
  23. J. B. Meigs, C. J. O'Donnell, G. H. Tofler et al., “Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study,” Diabetes, vol. 55, no. 2, pp. 530–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Zietz, C. Buechler, W. Drobnik, H. Herfarth, J. Schölmerich, and A. Schäffler, “Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels,” Endocrine Research, vol. 30, no. 3, pp. 443–453, 2004. View at Publisher · View at Google Scholar
  25. H. Kimura, F. Gejyo, Y. Suzuki, S. Suzuki, R. Miyazaki, and M. Arakawa, “Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy,” Kidney International, vol. 54, no. 5, pp. 1659–1669, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. B. Meigs, J. Dupuis, C. Liu et al., “PAI-1 gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample,” Obesity, vol. 14, no. 5, pp. 753–758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. H. Al-Hamodi, R. Saif-Ali, I. S. Ismail, K. A. Ahmed, and S. Muniandy, “Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian Subjects,” Journal of Clinical Biochemistry and Nutrition. In press. View at Publisher · View at Google Scholar
  28. W. Ahmed, M. Malik, I. Saeed et al., “Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction,” Molecular Biology Reports, vol. 38, no. 4, pp. 2541–2548, 2011. View at Publisher · View at Google Scholar
  29. L. Lovrecic, S. Ristic, N. Starcevic-Cizmarevic et al., “PAI and TPA gene polymorphisms in multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 2, pp. 243–247, 2008. View at Publisher · View at Google Scholar
  30. A. Gurkan, G. Emingil, B. H. Saygan et al., “Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis,” Journal of Periodontology, vol. 78, no. 7, pp. 1256–1263, 2007. View at Publisher · View at Google Scholar